Walleye Trading’s Aimmune Therapeutics AIMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
Sell
-3,500
Closed -$58K 4912
2020
Q2
$58K Sell
3,500
-6,200
-64% -$105K ﹤0.01% 3747
2020
Q1
$140K Buy
9,700
+4,700
+94% +$120K ﹤0.01% 2899
2019
Q4
$167K Sell
5,000
-1,500
-23% -$41.9K ﹤0.01% 3278
2019
Q3
$136K Sell
6,500
-11,200
-63% -$229K ﹤0.01% 3175
2019
Q2
$369K Buy
+17,700
New +$364K ﹤0.01% 2441

Other funds holding AIMT

Walleye Trading's AIMT Position: Q2 2020 in Review

Walleye Trading sold out of Aimmune Therapeutics (AIMT) in Q2 2020, closing a stake of 7,240 shares — an estimated $123K sold.

Walleye Trading first reported a position in AIMT in Q1 2020 and held it in 1 quarter. The position peaked at $104K in Q1 2020. 165 funds tracked by Wall St. Rank hold AIMT as of Q2 2020.

  • Walleye Trading reported no remaining Aimmune Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Walleye Trading sold 7,240 Aimmune Therapeutics shares in Q2 2020, an estimated $123K.
  • Walleye Trading first reported a position in Aimmune Therapeutics in Q1 2020 and held it in 1 quarter.
  • Walleye Trading's Aimmune Therapeutics position peaked at $104K in Q1 2020.
  • 165 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2020.

Based on Walleye Trading's 13F filing for Q2 2020, filed 14 Aug 2020.